Skip to content

Clinical study of targeting prefrontal cortex transcranial alternating current stimulation in improving insomnia in patients with gastrointestinal tumors

Clinical study of targeting prefrontal cortex transcranial alternating current stimulation in improving insomnia in patients with gastrointestinal tumors

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500109763
Enrollment
Unknown
Registered
2025-09-24
Start date
2025-09-24
Completion date
Unknown
Last updated
2025-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

insomnia

Interventions

Test group (tACS group):Professional trainers will clean the scalp and position the electrode cap to the corresponding position of the patients prefrontal cortex (Fz, Fp1, Fp2, F7, F8)
Turn on the device and confirm that the electrode impedance < 5 kO
The tACS group was given 2mA, 5Hz frequency alternating current stimulation for 20 min/day, 5 days/week for a total of 2 weeks (10 sessions in total), followed by a 2-week follow-up period
Control group (pseudostimulation group):The pseudo-stimulation group was given very low-intensity stimulation, making it difficult for patients to detect the presence of stimuli, and the rest of the p
Real-time EEG monitoring will also be performed during treatment, and venous blood will be collected before treatment and at the end of 2 weeks of treatment.

Sponsors

Naval Medical Center of PLA
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients aged between 18-75 years old, clinically diagnosed with gastrointestinal tumors with moderate to severe insomnia symptoms, insomnia duration of at least 1 month, expected survival of more than 3 months, clear consciousness and ability to cooperate with treatment and evaluation.

Exclusion criteria

Exclusion criteria: Severe neurological diseases (stroke, epilepsy, Parkinson's disease, etc.); History of psychiatric disorders (depression, anxiety, schizophrenia, etc.); Participating in other clinical trials or treatments that affect sleep at the same time; Severe liver and kidney insufficiency or other vital organ failure; Contraindications to tACS (pacemaker, intracranial metal implantation, etc.).

Design outcomes

Primary

MeasureTime frame
Pittsburgh Sleep Quality Index;

Secondary

MeasureTime frame
Hamilton Depression Rating Scale (HAMD);electroencephalogram,EEG;Insomnia Severity Index (ISI) score;sleep onset latency (SOL);total sleep time (TST);sleep efficiency;sleep quality;SF-36 health status score;daily interference;numeric rating scale (NRS);Hamilton Anxiety Scale (HAMA);

Countries

China

Contacts

Public ContactHaiyan Yue

Naval Medical Center of PLA

haiyanyuemd@126.com+86 21 8181 5171

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026